MX2021011699A - Derivados de quinolina y su uso para el tratamiento del cancer. - Google Patents
Derivados de quinolina y su uso para el tratamiento del cancer.Info
- Publication number
- MX2021011699A MX2021011699A MX2021011699A MX2021011699A MX2021011699A MX 2021011699 A MX2021011699 A MX 2021011699A MX 2021011699 A MX2021011699 A MX 2021011699A MX 2021011699 A MX2021011699 A MX 2021011699A MX 2021011699 A MX2021011699 A MX 2021011699A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- quinoline derivatives
- compounds
- quinoline
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente divulgación proporciona nuevos compuestos, composiciones que comprenden los compuestos y métodos de uso de los mismos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962825507P | 2019-03-28 | 2019-03-28 | |
| US201962952599P | 2019-12-23 | 2019-12-23 | |
| PCT/US2020/025160 WO2020198567A1 (en) | 2019-03-28 | 2020-03-27 | Quinoline derivatives and their use for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021011699A true MX2021011699A (es) | 2022-01-18 |
Family
ID=70334131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011699A MX2021011699A (es) | 2019-03-28 | 2020-03-27 | Derivados de quinolina y su uso para el tratamiento del cancer. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220144812A1 (es) |
| EP (1) | EP3946623A1 (es) |
| JP (1) | JP2022527279A (es) |
| KR (1) | KR20210151849A (es) |
| CN (1) | CN113891749A (es) |
| AU (1) | AU2020244861A1 (es) |
| BR (1) | BR112021019300A2 (es) |
| CA (1) | CA3134826A1 (es) |
| CL (2) | CL2021002501A1 (es) |
| CO (1) | CO2021014351A2 (es) |
| IL (1) | IL286649A (es) |
| MX (1) | MX2021011699A (es) |
| PH (1) | PH12021552389A1 (es) |
| SG (1) | SG11202110591SA (es) |
| WO (1) | WO2020198567A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240122941A1 (en) * | 2020-12-25 | 2024-04-18 | National Cancer Center | Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0109122D0 (en) * | 2001-04-11 | 2001-05-30 | Smithkline Beecham Spa | Novel compounds |
| CN101370782A (zh) * | 2005-12-12 | 2009-02-18 | 阿斯利康(瑞典)有限公司 | 烷基磺酰胺喹啉 |
| WO2007086799A1 (en) * | 2006-01-27 | 2007-08-02 | Astrazeneca Ab | Amide substituted quinolines |
| US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| CN101289460B (zh) * | 2008-06-06 | 2011-09-14 | 山东大学 | 有机硼酸类化合物及其作为荧光探针的应用 |
| PL2325181T3 (pl) * | 2008-07-10 | 2017-09-29 | General Incorporated Association Pharma Valley Project Supporting Organization | Inhibitor STAT3 zawierający jako składnik aktywny pochodną chinolinokarboksyamidu |
| EP3280708B1 (en) * | 2015-04-10 | 2021-09-01 | Araxes Pharma LLC | Substituted quinazoline compounds and methods of use thereof |
| KR20190040971A (ko) | 2016-07-25 | 2019-04-19 | 에피자임, 인코포레이티드 | Crebbp 관련 암 치료법 |
| EP3515449B1 (en) * | 2016-09-26 | 2023-07-12 | Dana-Farber Cancer Institute, Inc. | Quinoline derivatives as chromobox (cbx) protein inhibitors for treating cancer |
| EP3555070B1 (en) * | 2016-12-19 | 2023-08-09 | Epizyme, Inc. | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof |
-
2020
- 2020-03-27 MX MX2021011699A patent/MX2021011699A/es unknown
- 2020-03-27 BR BR112021019300A patent/BR112021019300A2/pt not_active IP Right Cessation
- 2020-03-27 WO PCT/US2020/025160 patent/WO2020198567A1/en not_active Ceased
- 2020-03-27 AU AU2020244861A patent/AU2020244861A1/en not_active Abandoned
- 2020-03-27 US US17/598,707 patent/US20220144812A1/en not_active Abandoned
- 2020-03-27 SG SG11202110591SA patent/SG11202110591SA/en unknown
- 2020-03-27 KR KR1020217034754A patent/KR20210151849A/ko not_active Ceased
- 2020-03-27 CN CN202080037338.8A patent/CN113891749A/zh active Pending
- 2020-03-27 CA CA3134826A patent/CA3134826A1/en active Pending
- 2020-03-27 PH PH1/2021/552389A patent/PH12021552389A1/en unknown
- 2020-03-27 EP EP20720657.4A patent/EP3946623A1/en not_active Withdrawn
- 2020-03-27 JP JP2021557381A patent/JP2022527279A/ja not_active Withdrawn
-
2021
- 2021-09-23 IL IL286649A patent/IL286649A/en unknown
- 2021-09-27 CL CL2021002501A patent/CL2021002501A1/es unknown
- 2021-10-26 CO CONC2021/0014351A patent/CO2021014351A2/es unknown
-
2022
- 2022-11-17 CL CL2022003206A patent/CL2022003206A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020198567A1 (en) | 2020-10-01 |
| CL2021002501A1 (es) | 2022-06-17 |
| CO2021014351A2 (es) | 2022-01-17 |
| BR112021019300A2 (pt) | 2021-12-14 |
| WO2020198567A8 (en) | 2020-11-19 |
| AU2020244861A1 (en) | 2021-11-18 |
| CA3134826A1 (en) | 2020-10-01 |
| PH12021552389A1 (en) | 2022-06-13 |
| KR20210151849A (ko) | 2021-12-14 |
| JP2022527279A (ja) | 2022-06-01 |
| IL286649A (en) | 2021-10-31 |
| SG11202110591SA (en) | 2021-10-28 |
| CN113891749A (zh) | 2022-01-04 |
| CL2022003206A1 (es) | 2023-07-07 |
| US20220144812A1 (en) | 2022-05-12 |
| EP3946623A1 (en) | 2022-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
| CO2020009861A2 (es) | Inhibidores pd-1/pd-l1 | |
| ECSP19052302A (es) | Derivados de benzooxazol como inmunomoduladores | |
| CO2018008761A2 (es) | Derivados de maitansinoide, conjugados de los mismos métodos de uso | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| MX394380B (es) | Compuestos dinucleótidos cíclicos para eltratamiento de cáncer | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| CO2017010890A2 (es) | Derivados de maitansinoide, conjugados del mismo, y metodos de uso | |
| MX384948B (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos. | |
| EA201791563A1 (ru) | Замещенные нуклеозидные производные, полезные в качестве агентов против рака | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| MX2018007774A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| CL2016002735A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| MX2018011419A (es) | Moduladores de receptores estrogénicos. | |
| MX381487B (es) | Ciertos inhibidores de la proteina quinasa. | |
| BR112017013568A2 (pt) | compostos bicíclicos fundidos para o tratamento de doenças | |
| MX2022007436A (es) | Inhibidores de la autotaxina y sus usos. | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| DOP2018000238A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
| MX391999B (es) | Piridinas y su uso en el tratamiento del cáncer. | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| MX2020000135A (es) | Nuevos compuestos de quinolinona. | |
| BR112017020374A2 (pt) | compostos bicíclicos fundidos para o tratamento de doença | |
| MX383386B (es) | Nuevos inhibidores de braf y uso de los mismos para el tratamiento de reacciones cutáneas. |